Article
Patients with rheumatoid arthritis (RA) all have a unique and diverse set of antibodies that are involved in the development of the disease.
All News
Article
Analysis of the German RABBIT registry shows that systemic inflammation, more so than disease activity, strongly influences all-cause mortality in patients with rheumatoid arthritis and prevalent interstitial lung disease (RA-ILD).
Article
Science Advances has reported that Duke University researchers have validated a biomarkers of osteoarthritis that may be identified 2 years before the appearance of radiographic OA.
Article
In an open-label, randomized, non-inferiority trial, rheumatoid arthritis patients in remission were subject to tapering of disease-modifying antirheumatic drugs (DMARDs), and while maintenance of remission was seen in some, many DMARD tapering patients did flare and were unable to maintain flare-free survival compared to those on stable conventional synthetic DMARDs.
Article
An investigational Toll-like receptor (TLR) antagonist was effective in reducing biomarkers and clinical symptoms of systemic lupus erythematosus (SLE) in a pilot trial, evidence that the innate immune system may hold the key to lupus pathophysiology.
Dr. John Cush
Tweet
“50% of pts with lupus nephritis are asymptomatic . You have to have a degree of kidney damage before you have proteinuria. Proteinuria does not correlate with intrarenal activity.” – Dr. A Fava #RNL2024 @rheumnow https://t.co/UOC8MZDM8N
Dr. John Cush
Tweet
Danish registry study shows positive association between maternal autoimmune Dz & childhood cancer. AID assoc w/ all child CA (OR=1.25), ALL (1.52), Burkitts (2.69), CNS tumors (1.45). RA mothers AID had higher risk of all cancers (OR=2.1) https://t.co/EYHyHzOboc https://t.co/FNRrvySI8P
Dr. John Cush
Tweet
Dr. Gabalawy: "How do you know what disease patients will develop in this preclinical autoimmunity state?"
@drdavidkarp ""it's like when weeds pop up in a garden, it's random ...if ACPA Ab pops up, you might have RA, if it's dsDNA, maybe lupus."" #RNL2024 https://t.co/kDkDaDRP8X
Dr. John Cush
Tweet
Low urinary IL16 levels at 12 months predicts kidney survival at 3 years better than proteinuria - @Andreafava @rheumnow #RNL2024 https://t.co/4GLmJQr46C
Dr. John Cush
Tweet
Rheum Chapter Notes
Dr. Jack Cush reviews this past week’s news and journal articles from https://t.co/V10S4oVFsv.
https://t.co/m6pkmYeiAl https://t.co/3cr3KwV1CP
Dr. John Cush
Tweet
UK Early Inflammatory Arthritis Audit of 20,060 RA pts (~12k on MTX; 5K csDMARD; ~2.5K no DMARD). Serious infections (SIE) hosp rate was 3.19/100PY, death 0.1/100PY. SIE risk incr w/ age, smoking, Hi DAS28 & HAQ. 1 unit DAS28, SI risk increased by 8% https://t.co/OrNh8oYE3y https://t.co/DqbeibNMbp
Dr. John Cush
Tweet
Tuesday Night Rheumatology: Mastering SLE https://t.co/lhExjSsKNA
Dr. John Cush
Tweet
FDA issued a drug safety warning linking thiopurine (AZA, 6MP) use in pregnancy & a rare risk of intrahepatic cholestasis of pregnancy (ICP). ICP has been reported in pts w/ CD, UC, or SLE; however thiopurines are not FDA approved for these Dx https://t.co/XKoUdy4sAR https://t.co/DSU9z0v7CZ
Dr. John Cush
Tweet
British Society for Rheumatology (BSR) presented (at the 2024 annual BSR meeting) new guidelines for the management of Behçet's disease - how to manage skin lesions, mouth ulcers, genital ulcers, serious eye, CNS & vascular involvement https://t.co/d0bjKuubym https://t.co/lqoTeTGqZ7
Dr. John Cush
Tweet
Spondyloarthritis Faculty Panel Q&A
Spondyloarthritis Faculty Panel Q&A - featuring Drs. Eric Ruderman, Lihi Eder, and Lianne Gensler; moderated by Dr. Artie Kavanaugh
https://t.co/6RFkyO72e1 https://t.co/CJ174sETFv
Dr. John Cush
Tweet
Future Therapy of Axial Spondyloarthritis
https://t.co/wjrlkuu0ds https://t.co/jQ12eTpT2l
Dr. John Cush
Tweet
Predicting Infection in Lupus Nephritis
Machine learning (ML) models were applied to 3 cohorts of lupus nephritis (LN) patients and established algorithms to predict co-infection in LN.
https://t.co/BnV7jVfqj1 https://t.co/LYQd6w1DvD
Dr. John Cush
Tweet
Our final TNR for the month of April will take place on 4/30 at 6:30pm ET.
Mastering SLE
Rethinking Pre-Clinical Disease in Lupus - David Karp, MD
Biology and Rx of Lupus Flares - Michelle Kahlenberg, MD
Current/Future Biomarkers in SLE - Andrea Fava, MD
https://t.co/j05QmWg17f https://t.co/jDvP0iTS8T
Dr. John Cush
Tweet
Predicting CKD Outcomes in Lupus Nephritis
An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class.
https://t.co/UHNqj6WTXn https://t.co/IOc0Gv21FM
Dr. John Cush
Tweet
In biologic-naïve active PsA pts Rx w/ guselkumab & achieving enthesitis (ER) or dactylitis resolution (DR), had better PRO outcomes. GUS - ER or DR was assoc w/ minimal pain (p < 0.001), normalized HAQ-DI (p < 0.001), , better FACIT-Fatigue responses https://t.co/HymI7CBfXh https://t.co/dYk9qXdVpt
